Loading…
Loading…
Align Technology, Inc. (NASDAQ: ALGN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 2,293 call options on the stock. This represents an increase of 72% compared to the typical daily volume of 1,334 call options. Analysts Set New Price Targets A number of analysts recently commented
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following financial conference. The presentation will be webcast live via the Investor Relations section of Align's website at ht.
TEMPE, Ariz. & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Quentin Blackford, President and Chief Executive Officer of iRhythm Technologies, as a director effective immediat.
Canada Pension Plan Investment Board bought a new position in Align Technology, Inc. (NASDAQ: ALGN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,510 shares of the medical equipment provider's stock, valued at approximately $4,471,000. Other institutional
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock?
On August 17, 2026, Align Technology Inc (ALGN) shares fell 5.6%, bringing the current price to $171.16. The stock has experienced a 52-week range of $122.00 to
Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.
ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.